MALVERN, Pa., Nov 03, 2008 (BUSINESS WIRE) ------Nine Months Ended September 30, 2008 Sales of $56.1 Million Reflect 32% Growth Over Same Period 2007

Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, reported financial results for the three and nine months ended September 30, 2008. Product sales for the three months ended September 30, 2008 increased 42% to $20.6 million, as compared to $14.5 million for the same period in 2007. Product sales for the nine months ended September 30, 2008 increased 32% to $56.1 million, as compared to $42.5 million for the same period in 2007.

Sales growth for the reported periods in 2008 was primarily attributable to increased sales of our VITOSS(R) FOAM and VITAGEL(R) product portfolios in the U.S. as we further develop our U.S. field sales network. Approximately 65% and 62% of our product sales during the three and nine months ended September 30, 2008, respectively, were from products based upon our VITOSS FOAM platform co-developed with Kensey Nash Corporation, as compared to approximately 62% and 61% of product sales during the same respective periods in 2007. Of the 65% of product sales contributed by VITOSS FOAM products during the third quarter of 2008, approximately 20% was from sales of the VITOSS Bioactive FOAM strip product that was fully launched in the second quarter of 2008. VITAGEL contributed approximately 23% and 24% of product sales, respectively, for the three and nine months ended September 30, 2008, as compared to approximately 20% of product sales during each of the three and nine months ended September 30, 2007, respectively.

Gross profit for the three months ended September 30, 2008 and 2007 was $13.9 million and $9.6 million, respectively. As a percentage of sales, gross profit was 68% and 66% for the three months ended September 30, 2008 and 2007, respectively. Gross profit for the nine months ended September 30, 2008 was $37.2 million, as compared to $27.8 million for the same period in 2007. As a percentage of sales, gross profit was 66% for both of the nine month periods ended September 30, 2008 and 2007. The increase in the gross profit margin for the three months ended September 30, 2008, as compared to the corresponding period in 2007, primarily reflects more favorable product mix and lower VITAGEL royalty expense as a percentage of product sales.

Operating expenses for the three months ended September 30, 2008 and 2007 were $15.1 million and $11.9 million, respectively, representing a 27% increase in operating expenses as compared to a 42% increase in product sales and a 44% increase in gross profit over the three months ended September 30, 2007. For the nine months ended September 30, 2008 and 2007, operating expenses were $45.7 million and $36.3 million, respectively, representing a 26% increase in operating expenses as compared to a 32% increase in product sales and a 34% increase in gross profit over the nine months ended September 30, 2007. The increase in operating expenses for the three and nine months ended September 30, 2008 was primarily due to higher selling and marketing expense, including salary and benefit costs incurred by expanding our field sales team in order to support the growth of U.S. product sales, as well as higher commissions paid in the U.S. as a result of increased product sales in 2008. The number of our direct sales representatives increased from 82 at September 30, 2007 to 89 at September 30, 2008.

The operating loss for the three months ended September 30, 2008 decreased to $1.2 million from $2.3 million for the three months ended September 30, 2007. The operating loss for each of the nine month periods ended September 30, 2008 and 2007 was $8.5 million. The decrease in the operating loss for the three months ended September 30, 2008 as compared to the corresponding period in 2007 primarily resulted from increased sales and gross profit, partly offset by increased selling & marketing expenses.

The net loss for the three months ended September 30, 2008 decreased to $1.7 million from $18.9 million for the three months ended September 30, 2007. The net loss per common share for the three months ended September 30, 2008 and 2007 was $0.02 and $0.27, respectively, based upon 75.8 million and 70.7 million common shares outstanding, respectively. The decrease in the net loss for the three months ended September 30, 2008, as compared to the same period in 2007, was due to: (i) the net loss for three months ended September 30, 2007 included a one time charge of $16.6 million for the repurchase of our revenue interest obligation from Royalty Trust on July 30, 2007, and (ii) increased sales and gross profit for the three months ended September 30, 2008. The net loss for the nine months ended September 30, 2008 and 2007 was $9.5 million and $25.0 million, respectively. The net loss per common share for the nine months ended September 30, 2008 and 2007 was $0.13 and $0.39, respectively, based upon 75.8 million and 64.5 million common shares outstanding, respectively. The net loss for nine months ended September 30, 2007 included a one time charge of $16.6 million as described above.

Cash, cash equivalents and investments were $36.9 million at September 30, 2008 in comparison to cash, cash equivalents and investments of $48.4 million at December 31, 2007. For the nine months ended September 30, 2008, the net cash and cash equivalents used in operating activities were $11.7 million, compared to $9.3 million for the nine months ended September 30, 2007. Net cash and cash equivalents used in operating activities for the nine months ended September 30, 2008 increased as compared with the nine months ended September 30, 2007 primarily due to an increase in accounts receivable.

Conference Call

Antony Koblish, President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host a conference call at 8:30 a.m. Eastern Time on November 4, 2008 to review and discuss the third quarter 2008 financial results and update guidance for 2008. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675; the conference identification number is 67743061. Listeners are advised to dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning November 4, 2008 at 11:30a.m. Eastern Time, and ending November 11, 2008, at 11:59p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706)645-9291. The replay identification number is 67743061.

About the Company

Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, VITAGEL(R) Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow, and VITASURE(TM) Absorbable Hemostat. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS(R) Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures. We work jointly with Kensey Nash Corporation to develop and commercialize certain products based on our VITOSS platform, we market VITAGEL under a license agreement, we market VITASURE Absorbable Hemostat under a distribution rights agreement, and we continue to pursue similar relationships.

Disclosure Notice

This press release may contain forward-looking statements regarding Orthovita's current expectations of future events that involve risks and uncertainties, including, without limitation, the development, regulatory clearance or approval, demand and market acceptance of our products, including CORTOSS; the development of our sales network; and other aspects of our business. Such statements are based on management's current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference are listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K under the caption "Risk Factors". Further information about these and other relevant risks and uncertainties may be found in Orthovita's filings with the SEC, all of which are available from the SEC as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements.

 ORTHOVITA,
   INC. AND SUBSIDIARIES Summary Financial Information (Unaudited) Statements of Operations Data: Three Months Ended Nine Months
   Ended September 30, September 30, 2008 2007 2008 2007 PRODUCT SALES $ 20,563,081 100 % $ 14,467,687 100 % $ 56,068,078 100
   % $ 42,470,316 100 % COST OF SALES 6,682,197 32 % 4,848,347 34 % 18,850,313 34 % 14,630,549 34 % GROSS PROFIT 13,880,884 68
   % 9,619,340 66 % 37,217,765 66 % 27,839,767 66 % OPERATING EXPENSES: General & administrative expenses 2,671,559 13 %
   2,850,379 20 % 8,202,293 15 % 8,158,482 19 % Selling & marketing expenses 10,957,284 53 % 7,906,123 55 % 32,236,273 57
   % 23,632,746 56 % Research & development expenses 1,456,380 7 % 1,127,365 8 % 5,292,670 9 % 4,539,093 11 % Total operating
   expenses 15,085,223 73 % 11,883,867 82 % 45,731,236 82 % 36,330,321 86 % OPERATING LOSS (1,204,339 ) (6 %) (2,264,527 ) (16
   %) (8,513,471 ) (15 %) (8,490,554 ) (20 %) INTEREST EXPENSE (814,013 ) (4 %) (507,100 ) (4 %) (1,976,195 ) (4 %) (634,649
   ) (1 %) REVENUE INTEREST EXPENSE - - (85,209 ) (1 %) - - (756,703 ) (2 %) GAIN/(LOSS) ON SALE OF ASSETS 74,074 <1 % - -
   (71,909 ) (<1 %) 372,375 1 % CHARGE FOR REPURCHASE OF REVENUE INTEREST OBLIGATION - - (16,605,029 ) (115 %) - - (16,605,029
   ) (39 %) INTEREST INCOME 264,517 1 % 544,292 4 % 1,075,520 2 % 1,082,598 3 % LOSS BEFORE INCOME TAX (1,679,761 ) (8 %) (18,917,573
   ) (131 %) (9,486,055 ) (17 %) (25,031,962 ) (59 %) INCOME TAX EXPENSE (14,350 ) (<1 %) - - (43,050 ) (<1 %) - - NET
   LOSS $ (1,694,111 ) (8 %) $ (18,917,573 ) (131 %) $ (9,529,105 ) (17 %) $ (25,031,962 ) (59 %) NET LOSS PER SHARE, BASIC AND
   DILUTED $ (0.02 ) $ (0.27 ) $ (0.13 ) $ (0.39 ) SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON 75,820,540
   70,728,955 75,790,134 64,507,337 SHARE 

 ORTHOVITA, INC. AND SUBSIDIARIES Summary Financial Information (Unaudited)
   (Audited) Balance Sheet Data: September 30, 2008 December 31, 2007 Cash and cash equivalents $ 11,180,543 $ 10,185,775 Short-term
   investments 23,200,254 38,222,113 Accounts receivable, net 10,393,766 8,437,917 Inventories 18,503,133 15,611,769 Other current
   assets 561,895 633,058 Total current assets 63,839,591 73,090,632 Long-term investments 2,489,003 - Property and equipment,
   net 11,653,730 8,252,394 License & technology intangibles, net 12,713,814 8,149,608 Other assets 690,026 724,504 Total
   assets $ 91,386,164 $ 90,217,138 Current liabilities $ 10,950,513 $ 11,281,583 Notes payable, net of debt discount 33,808,180
   23,895,376 Other long-term liabilities 261,838 510,762 Total liabilities 45,020,531 35,687,721 Total shareholders' equity
   46,365,633 54,529,417 Total liabilities and shareholders' equity $ 91,386,164 $ 90,217,138 Cash Flow Data: Nine Months Ended
   September 30, 2008 2007 Net cash used in operating activities $ (11,737,273 ) $ (9,320,726 ) Net cash provided by (used in)
   investing activities $ 2,980,710 $ (25,302,124 ) Net cash provided by financing activities $ 10,146,948 $ 35,051,949 Effect
   of exchange rate changes on cash and cash equivalents $ (395,617 ) $ 34,114 

SOURCE: Orthovita, Inc.

 Orthovita,
   Inc. Albert J. Pavucek, Jr. Chief Financial Officer 610-640-1775 or 800-676-8482 

Copyright Business Wire 2008 **********************************************************************
   As of Thursday, 10-30-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a
   DOWNTREND on 10-03-2008 for VITA @ $2.42. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com
   SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights
   reserved.